Skip to main content

Profile: Kevin Garey

Kevin Garey
Kevin W. Garey, Pharm.D., M.S., FASHP
Chair, Department of Pharmacy Practice and Translational Research
Professor of Pharmacy Practice
University of Houston College of Pharmacy
Health and Biomedical Sciences Building 2, Room 4039
4849 Calhoun
College of Pharmacy
Houston, TX 77204-5000
832-842-8386
832-842-8383 (Fax)

KGarey@uh.edu

Education

Bachelor of Science in Pharmacy, 1991-95, Dalhousie University, Halifax, Nova Scotia

Doctorate of Pharmacy, 1995-97, University at Buffalo, Buffalo, NY

M.S. in Biometry, 2007, University of Texas School of Public Health, Houston, TX

Research Interests

  • Infectious disease epidemiology
  • Post-operative infections
  • Biofilm activity of antimicrobials
  • Clostridium difficile infection

Awards & Honors

  • Top 10 Papers in Mycology, ICAAC 2014, Washington, D.C. ("T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial," Clin Infect Dis. 2015 Mar 15;60(6):892-9. doi: 10.1093/cid/ciu959. Epub 2015 Jan 12. PMID: 25586686)
  • Faculty Leadership Award, University of Houston Chapter of Phi Lambda Sigma Pharmacy Leadership Society, 2013
  • Impact Paper of the Year, Society of Infectious Diseases Pharmacists, 2012 ("A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection." J Antimicrob Chemother. 2011 Dec;66(12):2850-5. PubMed abstract)
  • Fellow, American Society of Health-System Pharmacists, 2012
  • Faculty Research Excellence Award, UH College of Pharmacy, 2007
  • Society of Infectious Diseases Pharmacists Impact Paper in Infectious Diseases, 2007
  • Literature Award in Drug Therapy, American Society of Health-System Pharmacists Research & Education Foundation, 2007
  • Pharmacotherapy Paper of the Year Award, Society of Infectious Diseases Pharmacists, 2007
  • UH College of Pharmacy Rho Chi Teacher Excellence Award, 2003
  • UH College of Pharmacy Faculty Teaching Excellence Award, 2003
  • Rho Chi member, 2003
  • Who's Who in Medicine and Healthcare, 2003

Courses

  • Pharm.D.: Lecturer for Drug Therapeutics, Pharmacodynamics, Research Methods, Infectious Disease elective (course coordinator), OTC Agents, and Literature Evaluation
  • Graduate Programs: Lecturer for Research Seminar in Pharmacy Administration, Pharmacy Administration II, Seminar Series in Healthcare Leadership (course coordinator), Residency Teaching Certificate Program, and Introduction to Health System Management (course coordinator)

Selected Publications (since 2010)

Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 May 30. pii: S0924-8579(16)30117-0. doi: 10.1016/j.ijantimicag.2016.04.026. [Epub ahead of print] Review. PMID: 27283730

Shah DN, Aitken SL, Barragan LF, Bozorgui S, Goddu S, Navarro ME, Xie Y, DuPont HL, Garey KW. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016 Jul;93(3):286-9. doi: 10.1016/j.jhin.2016.04.004. Epub 2016 Apr 20. PMID: 27209056

Gorbach C, Blanton L, Lukawski B, Varkey AC, Pitman P, Garey KW. Benchmarking and medication error rates. Am J Health Syst Pharm. 2016 Jun 1;73(11):746. doi: 10.2146/ajhp150961. PMID: 27208057

Endres BT, Bassères E, Memariani A, Chang L, Alam MJ, Vickers RJ, Kakadiaris IA, Garey KW. A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile. Anaerobe. 2016 Apr 21;40:10-14. doi: 10.1016/j.anaerobe.2016.04.013. [Epub ahead of print] PMID: 27108094

Thabit AK, Alam MJ, Khaleduzzaman M, Garey KW, Nicolau DP. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016 Apr 12;15:22. doi: 10.1186/s12941-016-0140-6. PMID: 27071986

Endres BT, Bassères E, Khaleduzzaman M, Alam MJ, Chesnel L, Garey KW. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 2016 May 23;60(6):3519-23. doi: 10.1128/AAC.00211-16. Print 2016 Jun. PMID: 27021314

Bassères E, Endres BT, Khaleduzzaman M, Miraftabi F, Alam MJ, Vickers RJ, Garey KW. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 2016 May;71(5):1245-51. doi: 10.1093/jac/dkv498. Epub 2016 Feb 18. PMID: 26895772

Garey KW, Aitken SL, Gschwind L, Goddu S, Xie Y, Duff C, Barbut F, Shah DN, DuPont HL. Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. J Clin Gastroenterol. 2016 Jan 19. [Epub ahead of print] PMID: 26796081

Philip A, Desai A, Nguyen PA, Birney P, Colavecchia A, Karralli R, Smith L, Lorimer D, Burgess G, Munch K, Daniel N, Lionetti J, Garey KW. Evaluating pharmacy leader development through the seven action logics. Am J Health Syst Pharm. 2016 Jan 15;73(2):82-5. doi: 10.2146/ajhp150162. PMID: 26721538

Sayles C, Hickerson SC, Bhat RR, Hall J, Garey KW, Trivedi MV. Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer: A Systematic Review. Nutr Clin Pract. 2016 Apr;31(2):171-9. doi: 10.1177/0884533615611857. Epub 2015 Oct 27. Review. PMID: 26507188

Gorbach C, Blanton L, Lukawski BA, Varkey AC, Pitman EP, Garey KW. Frequency of and risk factors for medication errors by pharmacists during order verification in a tertiary care medical center. Am J Health Syst Pharm. 2015 Sep 1;72(17):1471-4. doi: 10.2146/ajhp140673 PMID: 26294240

Aitken SL, Alam MJ, Khaleduzzaman M, Walk ST, Musick WL, Pham VP, Christensen JL, Atmar RL, Xie Y, Garey KW. In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect Control Hosp Epidemiol. 2015 Nov;36(11):1318-23. doi: 10.1017/ice.2015.187. Epub 2015 Aug 20. Erratum in: Infect Control Hosp Epidemiol. 2016 Jan;37(1):124. Khaleduzzuman, Mohammed [corrected to Khaleduzzaman, Mohammed]. PMID: 26288985

Pham VP, Luce AM, Ruppelt SC, Wei W, Aitken SL, Musick WL, Roux RK, Garey KW. Age-Stratified Treatment Response Rates in Hospitalized Patients with Clostridium difficile Infection Treated with Metronidazole. Antimicrob Agents Chemother. 2015 Oct;59(10):6113-6. doi: 10.1128/AAC.00816-15. Epub 2015 Jul 20. PMID: 26195522

Blee J, Roux RK, Gautreaux S, Sherer JT, Garey KW. Dispensing inhalers to patients with chronic obstructive pulmonary disease on hospital discharge: Effects on prescription filling and readmission. Am J Health Syst Pharm. 2015 Jul 15;72(14):1204-8. doi: 10.2146/ajhp140621. PMID: 26150570

Beyda ND, Liao G, Endres BT, Lewis RE, Garey KW. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrob Agents Chemother. 2015 Sep;59(9):5405-12. doi: 10.1128/AAC.00624-15. Epub 2015 Jun 22. PMID: 26100700

Philip A, Gessner-Wharton M, Birney P, Blee J, Desai A, Gorbach C, Karralli R, Lorimer D, Munch K, Nweke G, Parekh S, Puebla M, Cox R, Pitman EP, Garey KW. Pharmacy Practice Model Initiative task force report: Improving participation in a survey on hospital pharmacy practices in Texas. Am J Health Syst Pharm. 2015 Jun 15;72(12):1053-7. doi: 10.2146/ajhp140471. PMID: 26025997

Nesher L, Hadi CM, Salazar L, Wootton SH, Garey KW, Lasco T, Luce AM, Hasbun R. Epidemiology of meningitis with a negative CSF Gram stain: under-utilization of available diagnostic tests. Epidemiol Infect. 2016 Jan;144(1):189-97. doi: 10.1017/S0950268815000850. Epub 2015 May 20. PMID: 25989841

Reply to Bauer and Goff. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. Clin Infect Dis. 2015 Aug 1;61(3):487-8. doi: 10.1093/cid/civ357. Epub 2015 May 5. No abstract available. PMID: 25944341

Kilic A, Alam MJ, Tisdel NL, Shah DN, Yapar M, Lasco TM, Garey KW. Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples. Ann Lab Med. 2015 May;35(3):306-13. doi: 10.3343/alm.2015.35.3.306. Epub 2015 Apr 1. PMID: 25932438

Na X, Martin AJ, Sethi S, Kyne L, Garey KW, Flores SW, Hu M, Shah DN, Shields K, Leffler DA, Kelly CP. A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection. PLoS One. 2015 Apr 23;10(4):e0123405. doi: 10.1371/journal.pone.0123405. eCollection 2015. PMID: 25906284

Yu H, Chen K, Wu J, Yang Z, Shi L, Barlow LL, Aronoff DM, Garey KW, Savidge TC, von Rosenvinge EC, Kelly CP, Feng H. Identification of toxemia in patients with Clostridium difficile infection. PLoS One. 2015 Apr 17;10(4):e0124235. doi: 10.1371/journal.pone.0124235. eCollection 2015. PMID: 25885671

Philip A, Green M, Hoffman T, Gautreaux S, Wallace D, Roux R, Garey KW. Expansion of clinical pharmacy through increased use of outpatient pharmacists for anticoagulation services. Am J Health Syst Pharm. 2015 Apr 1;72(7):568-72. doi: 10.2146/ajhp140404. PMID: 25788511

Martinson JN, Broadaway S, Lohman E, Johnson C, Alam MJ, Khaleduzzaman M, Garey KW, Schlackman J, Young VB, Santhosh K, Rao K, Lyons RH Jr, Walk ST. Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology. J Clin Microbiol. 2015 Apr;53(4):1192-7. doi: 10.1128/JCM.03591-14. Epub 2015 Jan 28. PMID: 25631804

Garey KW, Aitken SL, Dima-Ala A, Beyda ND, Kuper K, Xie Y, Koo HL. Echinocandin use in hospitalized patients: a multi-institutional study. Am J Med Sci. 2015 Apr;349(4):316-20. doi: 10.1097/MAJ.0000000000000412. PMID: 25607510

Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015 Mar 15;60(6):892-9. doi: 10.1093/cid/ciu959. Epub 2015 Jan 12. PMID: 25586686

Aitken SL, Hemmige VS, Koo HL, Vuong NN, Lasco TM, Garey KW. Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship. Diagn Microbiol Infect Dis. 2015 Jan;81(1):4-8. doi: 10.1016/j.diagmicrobio.2014.09.025. Epub 2014 Oct 2. PMID: 25445120

Jacobs DM, Kuper K, Septimus E, Arafat R, Garey KW. Assessment of Antimicrobial Stewardship Activities in a Large Metropolitan Area. J Pharm Pract. 2016 Jun;29(3):188-93. doi: 10.1177/0897190014549842. Epub 2014 Oct 13. PMID: 25312262

Bernhardt MB, Moffett BS, Johnson M, Tam VH, Thompson P, Garey KW. Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer. 2015 Jan;62(1):80-4. doi: 10.1002/pbc.25194. Epub 2014 Sep 27. PMID: 25263332

Jacobs DM, Beyda ND, Asuphon O, Alam MJ, Garey KW. Host factors and clinical outcomes of Candida colonization in critically ill patients. Mycopathologia. 2015 Feb;179(1-2):87-93. doi: 10.1007/s11046-014-9809-6. Epub 2014 Aug 31. PMID: 25173925

Aitken SL, Joseph TB, Shah DN, Lasco TM, Palmer HR, DuPont HL, Xie Y, Garey KW. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One. 2014 Jul 24;9(7):e102848. doi: 10.1371/journal.pone.0102848. eCollection 2014. PMID: 25057871

Wanat MA, Fleming ML, Fernandez JM, Garey KW. Education, training, and academic experience of newly hired, first-time pharmacy faculty members. Am J Pharm Educ. 2014 Jun 17;78(5):92. doi: 10.5688/ajpe78592. PMID: 24954932

Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15;59(6):819-25. doi: 10.1093/cid/ciu407. Epub 2014 May 30. PMID: 24879785

Koo HL, Van JN, Zhao M, Ye X, Revell PA, Jiang ZD, Grimes CZ, Koo DC, Lasco T, Kozinetz CA, Garey KW, DuPont HL. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol. 2014 Jun;35(6):667-73. doi: 10.1086/676433. Epub 2014 Apr 22. PMID: 24799643

Aitken SL, Beyda ND, Shah DN, Palmer HR, Lasco TM, Koo H, Garey KW. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother. 2014 Jun;48(6):683-90. doi: 10.1177/1060028014529928. Epub 2014 Mar 31. PMID: 24687545

Alam MJ, Anu A, Walk ST, Garey KW. Investigation of potentially pathogenic Clostridium difficile contamination in household environs. Anaerobe. 2014 Jun;27:31-3. doi: 10.1016/j.anaerobe.2014.03.002. Epub 2014 Mar 19. PMID: 24657158

Darkoh C, Turnwald BP, Koo HL, Garey KW, Jiang ZD, Aitken SL, DuPont HL. Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol. 2014 Apr;21(4):509-17. doi: 10.1128/CVI.00770-13. Epub 2014 Jan 29. PMID: 24477852

Wanat MA, Garey KW. A blueprint for transitioning pharmacy residents into successful clinical faculty members in colleges and schools of pharmacy. Am J Pharm Educ. 2013 Nov 12;77(9):200. doi: 10.5688/ajpe779200. Review. PMID: 24249862

Beyda ND, Alam MJ, Garey KW. Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. Diagn Microbiol Infect Dis. 2013 Dec;77(4):324-6. doi: 10.1016/j.diagmicrobio.2013.07.007. Epub 2013 Oct 14. PMID: 24135411

Patel TS, Crutchley RD, Tucker AM, Cottreau J, Garey KW. Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. HIV AIDS (Auckl). 2013 Jul 15;5:153-62. doi: 10.2147/HIV.S30948. Print 2013. PMID: 23888120

Jardin CG, Palmer HR, Shah DN, Le F, Beyda ND, Jiang Z, Garey KW.  Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Sep;85(1):28-32. doi: 10.1016/j.jhin.2013.04.017. Epub 2013 Jul 5.

Yeo QM, Crutchley R, Cottreau J, Tucker A, Garey KW. Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea. Drugs Today (Barc). 2013 Apr;49(4):239-52. doi: 10.1358/dot.2013.49.4.1947253.PMID: 23616951

Huang JS, Jiang ZD, Garey KW, Lasco T, Dupont HL. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother. 2013 Jun;57(6):2690-3. doi: 10.1128/AAC.00548-13. Epub 2013 Apr 1. PMID: 23545528

Shah DN, Bhatt NS, Welch JK, Koo HL, Garey KW. Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. J Hosp Infect. 2013 Apr;83(4):294-9. doi: 10.1016/j.jhin.2012.12.011. Epub 2013 Feb 20. PMID: 23433867

Natali BJ, Varkey AC, Garey KW, Liebl M. Impact of a pharmacotherapy alerting system on medication errors. Am J Health Syst Pharm. 2013 Jan 1;70(1):48-52. doi: 10.2146/ajhp120126. PMID: 23261900

Jiang ZD, Hoang LN, Lasco TM, Garey KW, Dupont HL. Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis. 2013 Apr;56(7):1059-60. doi: 10.1093/cid/cis1025. Epub 2012 Dec 7. PMID: 23223589

Haines LA, Putney KS, Varkey DA, Frost C, Pitman EP, Aparasu RR, Garey KW. Pilot of a patient-centered pharmacy practice model. Am J Health Syst Pharm. 2012 Nov 1;69(21):1860-1. doi: 10.2146/ajhp120132. PMID: 23111668

Beyda ND, Chuang SH, Alam MJ, Shah DN, Ng TM, McCaskey L, Garey KW. Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother. 2013 Feb;68(2):438-43. doi: 10.1093/jac/dks388. Epub 2012 Oct 19. Review. PMID: 23085777

Beyda ND, Lewis RE, Garey KW. Echinocandin Resistance in Candida Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches (July/August). Ann Pharmacother. 2012 Jul-Aug;46(7-8):1086-96. doi: 10.1345/aph.1R020. Epub 2012 Jul 17. Review.

Singh V, Arora V, Alam MJ, Garey KW. Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother. 2012 Aug;56(8):4360-4. doi: 10.1128/AAC.00544-12. Epub 2012 Jun 4. PMID: 22664967

Tran TT, Palmer HR, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 1;69(11):979-84.PMID: 22610031

Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, Garey KW. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012 Jun;56(6):3239-43. Epub 2012 Mar 12. PMID: 22411611

Le F, Arora V, Shah DN, Salazar M, Palmer HR, Garey KW. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy. 2012 Feb;32(2):129-34. doi: 10.1002/PHAR.1002. Epub 2012 Jan 24. PMID: 22392421

Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health. 2011 Jul;42(4):890-900.

Cottreau J, Tucker A, Crutchley R, Garey KW. Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol. 2012 Jan;6(1):17-23. Epub 2011 Nov 3.

Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, Dupont HL. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011 Dec;66(12):2850-5.

Palmer HR, Weston J, Gentry L, Salazar M, Putney K, Frost C, Tipton JA, Cottreau J, Tam VH, Garey KW. Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm. 2011 Nov 15;68(22):2170-4.

Mora AL, Salazar M, Pablo-Caeiro J, Frost CP, Yadav Y, Dupont HL, Garey KW. Moderate to High Use of Opioid Analgesics Are Associated With an Increased Risk of Clostridium difficile Infection. Am J Med Sci. 2012 Apr;343(4):277-80.

Crutchley RD, Gathe J, Mayberry C, Trieu A, Abughosh S, Garey KW. Risk Factors for Vitamin D Deficiency in HIV-Infected Patients in the South Central United States. AIDS Res Hum Retroviruses. 2012 May;28(5):454-9. Epub 2011 Oct 19.

Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, Garey KW. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011 Sep;66(9):2146-51.

Arora V, Kachroo S, Ghantoji SS, Dupont HL, Garey KW. High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect. 2011 Sep;79(1):23-6.

S Sethi, KW Garey, V Arora, S Ghantoji, P Rowan, M Smolensky, HL DuPont. Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after Clostridium difficile Infection. J Hosp Infect 2011;77:172-3

Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai. 2011 Jul;94(7):863-70.

Halton K, Arora V, Singh V, Ghantoji SS, Shah DN, Garey KW. Bacterial colonization on writing pens touched by healthcare professionals and hospitalized patients with and without cleaning the pen with alcohol-based hand sanitizing agent. Clin Microbiol Infect. 2011 Jun;17(6):868-9. doi: 10.1111/j.1469-0691.2011.03494.x.

Koo HL, Garey KW, Dupont HL. Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs. 2010 Jul;19(7):825-36. Review.

Garey KW, Jiang ZD, Ghantoji S, Tam VH, Arora V, DuPont HL. A common polymorphism in the interleukin-8 gene promoter is associated with increased risk for recurrent Clostridium difficile infection. Clin Infect Dis 2010; 51(12): 1406-10

Bhagunde P, Chang KT, Singh R, Singh V, Garey KW, Nikolaou M, Tam VH. Mathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother. 2010 Nov;54(11):4739-43.

Dupont HL, Garey KW. Clostridium difficile infection: an emerging epidemic with more questions than answers. Future Microbiol. 2010 Aug;5(8):1153-6.

Palmer HR, Cottreau JM, Garey KW, Hirsch EB, Musick WL, Tam VH, Yeh RF; Houston Infectious Diseases Network. Significant publications on infectious diseases pharmacotherapy in 2009. Am J Health Syst Pharm. 2010 Aug;67(15):e34-42. Review.

Cottreau J, Baker SF, DuPont HL, Garey KW. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther. 2010 Jul;8(7):747-60.

Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010 Sep;54(9):3717-22.

Shah D, Dang MD, Hasbun R, Koo HL, Jiang ZD, DuPont HL, Garey KW. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther. 2010 May;8(5):555-64. Review.

Crutchley RD, Miller J, Garey KW. Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother. 2010 May;44(5):878-84.

Jiang ZD, DuPont HL, La Rocco M, Garey KW. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol. 2010 Apr;63(4):355-8.

Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010 Apr;74(4):309-18. Review

Birtcher KK, Corbett SM, Pass SE, Coyle EA, Yeh RF, Tipton J, Garey KW; Academic Pharmacy Symposium. Symposium on roles of and cooperation between academic- and practice-based pharmacy clinicians. Am J Health Syst Pharm. 2010 Feb 1;67(3):231-8.

Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro JP, Garey KW. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar;54(3):1160-4.

Book Chapters

Aitken SL, Shah DN, Garey KW. Economic burden of Clostridium difficile infection. In: Clostridium difficile: New Challenges for an Old Foe. Tillotson GS, Weiss K (Eds). Future Medicine, London, UK. DOI: 10.2217/EBO.13.185 (2013). ISBN 978-1-78084-315-5

Garey KW. Clostridium difficile infection. In: Richardson M, Chant C, Chessman KH, Finks SW, Hemstreet BA, Hume AL, et al, eds. Pharmacotherapy Self-Assessment Program, 7th ed. Infectious Diseases. Lenexa, KS: American College of Clinical Pharmacy, 2012

Garey KW and Gerard L. Gastrointestinal infections. In: Helms R, Quan DJ, eds. Textbook of Therapeutics: Drug and Disease Management Eighth Edition. Lippincott, Williams & Wilkins, Inc. April 2006

Sprandel KA, Garey KW, Rodvold KA. Drug-Food Interactions. In: Piscitelli SC, Rodvold KA, eds. Drug Interactions in Infectious Diseases 2nd Edition. New Jersey: Humana Press Aug 2005

Garey KW, Rodvold KA. Drug-Food Interactions. In: Piscitelli SC, Rodvold KA, eds. Drug Interactions in Infectious Diseases. New Jersey: Humana Press Sept 2000

Presentations & Abstracts (since 2010)

Shah DN, Laine ME, Wei W, Smith LC, Palmer HR, Musick WL, Garey KW. Treatment Patterns in Hospitalized Patients with Multiple Clostridium difficile Infection Recurrences and Assessment of Ongoing Use of Pharmacologic Risk Factors. Abstract #1903 (poster presentation). 53rd ICAAC, September 10-13, 2013, Denver, CO

Shah DN, Esquer Z, Ruelas DJ, DuPont HL, Garey KW. Outcome of Patients with Clostridium difficile Infection in a Large Tertiary Care Hospital in Houston. Abstract #2422 (poster presentation). 53rd ICAAC, September 10-13, 2013, Denver, CO

Jacobs DM, Asuphon O, Beyda ND, Alam MJ, Garey KW. Host factors for Candida colonization in critically ill patients. Abstract #2441 (poster presentation). 53rd ICAAC, September 10-13, 2013, Denver, CO

Beyda ND, John J, Alam MJ, Kilic A, Lasco TM, Garey KW. Echinocandin resistant Candida glabrata; risk factors and outcomes in patients with Candidemia. Abstract M-220 (poster walk). 53rd ICAAC, September 10-13, 2013, Denver, CO

Aitken SL, Beyda ND, Shah DN, Lasco T, Koo H, Garey KW. Clinical practice patterns in hospitalized patients at risk for candidemia: implications for rapid Candida species detection methods. Abstract #2488 (poster presentation). 53rd ICAAC, September 10-13, 2013, Denver, CO

Aitken SL, Joseph TB, Shah DN, Palmer HR, Lasco T, DuPont HL, Garey KW. Healthcare resource utilization in patients with recurrent Clostridium difficile infection. Abstract #2154 (oral presentation). 53rd ICAAC, September 10-13, 2013, Denver, CO

Aitken SL, Shah DN, Davis B, Nurshazwani W, Savidge T, DuPont HL, Garey KW. Use of zolpidem, a γ-amino butyric acid receptor agonist, and risk of acquiring Clostridium difficile infection. Abstract #2087 (oral presentation). 53rd ICAAC September 10-13, 2013, Denver, CO

MJ Alam, A Anu, KW Garey. Environmental Investigation of Community Household Contamination of Clostridium difficile. ASM 113th General Meeting. Denver, CO. May 20, 2013

Aitken SL, Alam MJ, Garey KW. Environmental prevalence of Clostridium difficile at a university-affiliated teaching hospital in Houston, Texas. ASM 113th General Meeting. May 20, 2013. Denver, CO

ND Beyda, MJ Alam, KW Garey. Comparison of the T2 Biosystems Candida Assay and Automated Blood Culture in the Detection of Candida species Using Simulated Blood Cultures. ASM 113th General Meeting. May 20, 2013 Denver, CO

Beyda ND, Shah DN, Cottreau J, Salazar M, Frost C, Lasco TM, Garey KW. Aggregate measures of antifungal use in hospitalized patients: Defined daily doses vs. antimicrobial days. IDWeek 2012, October 17-21, 2012, San Diego, CA

Beyda ND, Kilic A, Alam MJ, Lasco TM, Garey KW. Molecular epidemiology and fluconazole susceptibility of Candida glabrata candidemia at a university-affiliated medical center. 52nd ICAAC, September 9-12, 2012, San Francisco, CA

Kilic A, Alam MJ, Tisdel NT, Shah DN, Yapar M, Lasco TM, Garey KW. Development and evaluation of a double multiplex real-time PCR method for simultaneous identification and toxigenic type characterization of C. difficile from stool samples. 52nd ICAAC, San Francisco, CA. September 9-12, 2012.

Shah DN, Bhatt NS, Chen E, Koo HL, DuPont HL, Garey KW. A risk index based on comorbid conditions and disease severity to predict mortality in patients with Clostridium difficile infection. 52nd ICAAC, San Francisco, CA. September 9-12, 2012.

Shah DN, Panchumarthi VK, Al-Jashaami LS, Koo HL, DuPont HL, Garey KW. Clinical characteristics of hospitalized patients with community-associated versus non-community-associated Clostridium difficile infection. 52nd ICAAC, San Francisco, CA. September 9-12, 2012.

Kilic A, Alam MJ, Tisdel NT, Shah DN, Yapar M, Lasco TM, Garey KW. Development and evaluation of a double multiplex real-time PCR method for detection of the Clostridium difficile toxin A, toxin B and binary toxin A. Anaerobe 2012, San Francisco, CA. June 27-July 1, 2012

Shah DN, Kilic A, Alam MJ, Darkoh C, De La Cabada J, Jiang ZD, DuPont HL, Garey KW. Characterization of Clostridium difficile strains from patients with mortality attributed to Clostridium difficile infection. Anaerobe 2012, San Francisco, CA. June 27-July 1, 2012.

Garey KW, Shah DN, Habib M, Lasco T. Clinical assessment of nanotechnology and miniaturized magnetic resonance to detect candidemia in hospitalized patients. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011.

Grimes CZ, Shah DN, Koo HL, DuPont HL, Garey KW. Validity of recommended criteria for attributable mortality associated with Clostridium difficile Infection. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011.

Shah DN, Dima-ala A, Dolormente K, Arora V, Garey KW. Incidence of antibiotic-associated diarrhea in hospitalized patients given broad spectrum antibiotics. 51st ICAAC, Chicago, IL. Sept. 17-20, 2011.

Shah DN, Koo HL, Lasco TM, Palmer HR, Garey KW. Assessment of attributable mortality rate of candidemia in candidemia pts with inpatient mortality. 51st ICAAC, Chicago, IL. Sept. 17-20, 2011.

D Shah, R Yau, J Weston, T Lasco, M Salazar, H Palmer, KW Garey. Pre-exposure to antifungals as a risk factor for fluconazole-non-susceptible Candida species in hospitalized patients with candidemia. 21st ECCMID / 27th ICC meeting, Milan, Italy. May 7-10, 2011

KW Garey, S Ghantoji, D Shah, M Habib, V Arora, ZD Jiang, H DuPont. A randomised, double-blind, placebo-controlled pilot study to assess the effect of rifaximin “chaser” to prevent recurrent diarrhoea in patients with Clostridium difficile infection. 21st ECCMID / 27th ICC meeting, Milan, Italy. May 7-10, 2011

W Santimaleeworagun, J Christensen, V Singh, DN Shah, KT Chang, VH Tam, and KW Garey. Molecular epidemiology of Clostridium difficile and prevalence of the NAP-1strain among patients admitted to a general and a private hospital in Houston, Texas USA. 21st ECCMID / 27th ICC meeting, Milan, Italy. May 7-10, 2011

Xu R, Salazar M, Weston JS, Shah DN, Putney KS, Garey KW. Susceptibility of Candida species in patients with candidemia. SCCM’s 40th Critical Care Congress, San Diego, CA. January 16-18, 2011.

De La Cabada J, Jiang ZD, Ghantoji SS, Garey KW, Lasco TM, Larocco M, Shah D, DuPont HL. Fecal lactoferrin in Clostridium difficile infection as a predictor of single bouts vs. recurrent disease (Podium presentation). IDSA 48th Annual Meeting, Vancouver, Canada. October 21-24, 2010

Tran TC, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey KW. Daptomycin dose-effect relationship against vancomycin-resistant enterococcal bacteremia. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010.

Gordon SM, Shah DN, Tran TC, Lasco T, Garey KW. Variations in time to blood culture positivity stratified by Candida species and fluconazole susceptibility. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010. (Oral)

Shah DN, Yau RW, Weston J, Lasco T, Salazar M, Palmer H, Garey KW. Utility of fluconazole as de-escalation therapy in patients with fluconazole-susceptible candidemia. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010.

Tran TC, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey KW. Evaluation of daptomycin PK/PD dose optimization protocol. 50th ICAAC, Boston MA. Sept. 12-15, 2010. (Oral)

Shah DN, Yau RW, Weston J, Xu R, Salazar M, Palmer H, Garey KW. Changes to empiric antifungal therapy based on susceptibility testing results. 50th ICAAC, Boston MA. Sept. 12-15, 2010.

Invited Presentations (since 2010)

Key Considerations for Improving Patient Outcomes with Antimicrobial Stewardship Programs. Idaho Society of Health Systems Pharmacists Annual meeting. March 6, 2016. Boise, ID

Updates in the treatment of C. difficile. ASHP Midyear Clinical Meeting 2015. Dec. 10, 2015. New Orleans, LA

Updates in the treatment of C. difficile. ID-Week 2015. Oct. 10, 2015. San Diego, CA

Clostridium difficile. Ongoing research and implications for best practice. Texas Department of Healthcare Safety Conference. Aug. 21, 2015. Bay City, TX

Tips for a successful research career. Temple University School of Pharmacy Research Day. Feb. 20, 2015. Philadelphia, PA

Management of Invasive Fungal Infections: Applying Evidence-based Strategies and Individualizing Antifungal Therapy. ASHP Midyear, Dec. 10, 2014. Anaheim, CA

Antibiotic management – Is it time to think differently with Clostridium difficile. ICAAC Workshop, Sept. 5, 2014. Washington, DC

New treatment strategies for C. difficile. Anaerobe 2014 Congress. Chicago, IL. July 1, 2014

Update in Infectious Diseases. ASHP Annual Meeting. Las Vegas, NV. June 1, 2014

Update on C. difficile. ASHP Midyear Meeting. Orlando, FL. Dec. 11, 2013

Appropriate dosing of antifungals. Trends in Medical Mycology (TIMM). Copenhagen, Denmark. Oct. 12, 2013

Mentoring pharmacy residents to successful clinical faculty. AACP Annual Meeting. Chicago, IL. July 15, 2013

Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR). European Center for Disease Prevention and Control (ECDC). Stockholm, Sweden. June 17-19, 2013

The Role of Laboratory Testing in Managing Fungal Infections. MAD-ID 2013 Annual Meeting. Orlando, FL. May 11, 2013

What’s the Poop on Clostridium difficile Infection in 2013. MAD-ID 2013 Annual Meeting. Orlando, FL. May 9, 2013

Infectious Diseases Update 2013. APhA Annual Meeting. Los Angeles, CA. March 3, 2013

Clostridium difficile infection: New drugs and new strategies. ASHP Midyear Clinical Meeting, Las Vegas NV. Dec. 4, 2012

Alternative treatments for Clostridium difficile associated diarrhea. ACCP Annual Meeting, Hollywood, FL. Oct. 22, 2012

Surgical Prophylaxis: Dosage Recommendations, Tissue Penetration, and Pharmacokinetic Considerations. 52nd ICAAC. San Francisco, CA Sept. 10, 2012

Using Antimicrobial Stewardship Programs to Optimize the Use of New Anti-infectives. ASHP Advantage Seminar Series. Presented at the annual meetings of:

Virginia Society of Health Systems Pharmacists, Wintergreen, VA. April 20, 2012
Louisiana Society of Health-Systems Pharmacists, New Orleans, LA. May 26, 2012
Idaho Society of Health-Systems Pharmacists, Sun Valley, ID. Sept. 30, 2012
New Hampshire Society of Health-Systems Pharmacists, Concord, NH. Oct. 8, 2012
Georgia Society of Health-Systems Pharmacists, Young Harris, GA. Oct. 19, 2012

Fidaxomicin and its place in the management of C. difficile infection. Greater New York Hospital Association. Webinar. March 14, 2012

Infectious Diseases Update 2012. APhA Annual Meeting. New Orleans, LA. March 11, 2011

Guideline and Literature Update in Infectious Diseases 2011 (Moderator and Presenter). ASHP Midyear Clinical Meeting, New Orleans LA. Dec. 7, 2011

Update on Fidaxomcin. Annual Meeting of the Society of Infectious Diseases Pharmacist. Chicago, IL. September 16, 2011

Preventing Health Care-Associated Infections. APhA Annual Meeting. Seattle, WA. March 28, 2011

Germ Nation: Infectious Disease Update 2010 (Encore), APhA Live. Memphis, TN. October 16, 2010

Infectious Diseases Update in Texas: From Bench to Bedside to Beyond (Moderator and presenter). 62th Annual Meeting of the Texas Society of Health System Pharmacists (TSHP), Galveston, TX. April 9, 2010

Germ nation: Infectious Disease Update. APhA Annual Meeting. Washington, DC. March 14, 2010

Professional Service & Affiliations

  • American College of Clinical Pharmacy
  • American Society of Health-System Pharmacists
  • Society of Infectious Diseases Pharmacists
  • American Society of Microbiology

Editorial Appointments

  • Associate Editor, Annals of Pharmacotherapy
  • Editorial Board Chair, Annals of Pharmacotherapy
  • Reviewer, Infection Control and Hospital Epidemiology, Annals of Pharmacotherapy, American Journal of Health System Pharmacy, American Journal of Preventive Medicine, Medical Principles and Practice, Pharmacotherapy, The Journal of Pharmacy Practice and Research, Therapeutics and Clinical Risk Management, Future Drugs, Journal of Antimicrobial Chemotherapy, BMC Infectious Diseases, Journal of Infection, American Journal of Tropical Medicine & Hygiene, Lancet, Medical Mycology, Clinical Infectious Diseases, Diagnostic Microbiology and Infectious Diseases, Digestive Diseases and Sciences, Critical Care, Archives of Internal Medicine, Scandinavian Journal of Infectious Diseases, Clinical Microbiology and Infection, Nature Reviews Gastroenterology and Hepatology, International Journal of Immunogenetics, Canadian Medical Association Journal